Helix BioPharma Corp. (TO:HBP) — Market Cap & Net Worth
Market Cap & Net Worth: Helix BioPharma Corp. (HBP)
Helix BioPharma Corp. (TO:HBP) has a market capitalization of $116.58 Million (CA$161.16 Million) as of May 4, 2026. Listed on the TO stock exchange, this Canada-based company holds position #18609 globally and #616 in its home market, demonstrating a 8.76% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Helix BioPharma Corp.'s stock price CA$2.11 by its total outstanding shares 76378098 (76.38 Million). Analyse cash flow conversion of Helix BioPharma Corp. to see how efficiently the company converts income to cash.
Helix BioPharma Corp. Market Cap History: 2015 to 2026
Helix BioPharma Corp.'s market capitalization history from 2015 to 2026. Data shows change from $552.51 Million to $116.58 Million (-14.12% CAGR).
Helix BioPharma Corp. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Helix BioPharma Corp.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of HBP by Market Capitalization
Companies near Helix BioPharma Corp. in the global market cap rankings as of May 4, 2026.
Key companies related to Helix BioPharma Corp. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Helix BioPharma Corp. Historical Marketcap From 2015 to 2026
Between 2015 and today, Helix BioPharma Corp.'s market cap moved from $552.51 Million to $ 116.58 Million, with a yearly change of -14.12%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$116.58 Million | -10.97% |
| 2025 | CA$130.94 Million | +166.29% |
| 2024 | CA$49.17 Million | -15.24% |
| 2023 | CA$58.01 Million | -4.55% |
| 2022 | CA$60.78 Million | -26.67% |
| 2021 | CA$82.88 Million | -40.00% |
| 2020 | CA$138.13 Million | -62.69% |
| 2019 | CA$370.18 Million | +152.83% |
| 2018 | CA$146.41 Million | -43.62% |
| 2017 | CA$259.68 Million | -38.96% |
| 2016 | CA$425.43 Million | -23.00% |
| 2015 | CA$552.51 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Helix BioPharma Corp. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $116.58 Million USD |
| MoneyControl | $116.58 Million USD |
| MarketWatch | $116.58 Million USD |
| marketcap.company | $116.58 Million USD |
| Reuters | $116.58 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Helix BioPharma Corp.
Helix BioPharma Corp. a clinical-stage biopharmaceutical company developing therapies in the field of immune-oncology in Canada. Its product pipeline comprises L-DOS47, a clinical-stage antibody-enzyme conjugate (AEC) that neutralizes the microenvironment of solid tumors; LDOS001, which is in phase I clinical trial to treat non-small cell lung cancer; LDOS002, which is in phase I/II clinical tria… Read more